Revance Therapeutics - Stock Price History | RVNC

Historical daily share price chart and data for Revance Therapeutics since 2021 adjusted for splits. The latest closing stock price for Revance Therapeutics as of September 27, 2021 is 29.66.
  • The all-time high Revance Therapeutics stock closing price was 40.78 on November 11, 2015.
  • The Revance Therapeutics 52-week high stock price is 33.83, which is 14.1% above the current share price.
  • The Revance Therapeutics 52-week low stock price is 22.89, which is 22.8% below the current share price.
  • The average Revance Therapeutics stock price for the last 52 weeks is 27.72.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Revance Therapeutics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 23.1684 16.0000 34.3000 12.4600 28.3400 74.61%
2019 14.3943 19.5100 20.3900 10.2200 16.2300 -19.37%
2018 27.8392 37.4000 37.4000 18.0600 20.1300 -43.69%
2017 23.9633 21.5500 36.3000 18.3000 35.7500 72.71%
2016 17.2917 33.3600 33.5900 12.5500 20.7000 -39.40%
2015 27.1282 16.6600 40.7800 15.0200 34.1600 101.65%
2014 25.9471 26.8500 38.9000 14.8900 16.9400 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.130B $0.015B
Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS? peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29